Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy | Zendy

Thorsten Kramm | Zendy; Balthasar Eberle | Zendy; Stefan Guth | Zendy; Eckhard Mayer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy

Author(s) -

Thorsten Kramm,

Balthasar Eberle,

Stefan Guth,

Eckhard Mayer

Publication year - 2005

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1016/j.ejcts.2005.09.007

Subject(s) - iloprost , medicine , pulmonary hypertension , cardiology , chronic thromboembolic pulmonary hypertension , anesthesia , prostacyclin

Pulmonary endarterectomy (PEA) is the standard therapy for patients with chronic thromboembolic pulmonary hypertension (CTEPH). In the immediate postoperative period, persistent pulmonary hypertension increases the risk of acute respiratory or right heart failure. In pulmonary arterial hypertension, prostanoid inhalation has been found to improve pulmonary hemodynamics, right ventricular function, gas exchange, and clinical outcome. We report the results of a double-blinded randomized trial with the aerosolized prostacyclin analogue iloprost in patients with residual pulmonary hypertension after PEA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research